Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 7Esophageal Neoplasms 1Endometrial Adenocarcinoma 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Bladder Urothelial Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 38Fluorouracil 37Radiotherapy 33Oxaliplatin 23Paclitaxel 20Irinotecan 18Leucovorin 17Docetaxel 17Capecitabine 10Neoadjuvant Therapy 9Surgical Procedures, Operative 8Cetuximab 8Chemotherapy, Adjuvant 7Radiation 6Carboplatin 6Immunohistochemistry 5Erlotinib Hydrochloride 5Biopsy 5Magnetic Resonance Spectroscopy 4Gene Expression Profiling 4Folfox protocol 4Epirubicin 4Drug Therapy 4pembrolizumab 3Trastuzumab 3Microarray Analysis 3Gefitinib 3Fluorodeoxyglucose F18 3Endoscopy, Digestive System 3ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma Of Esophagus × Ogivri × Clear all
NCT01196390 2026-06-02

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
203 enrolled 22 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡